Jason Yuen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jason Yuen has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
Kendall H. Lee
Department of Neurologic Surgery, Mayo Clinic, Rochester, USA
8 shared publications- Yoonbae Oh
Neural Engineering and Precision Surgery Laboratories (NEPS), Mayo Clinic
7 shared publications - Hojin Shin
Neural Engineering and Precision Surgery Laboratories (NEPS), Mayo Clinic
6 shared publications - Charles D. Blaha
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55905, USA; Neural Engineering and Precision Surgery Laboratories, Mayo Clinic, Rochester, MN, 55905, USA
5 shared publications Aaron E. Rusheen
Department of Neurosurgery, Johns Hopkins University, Baltimore, USA
4 shared publications- Abhinav Goyal
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, United States
4 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in Movement Disorders
Preoperative Functional Imaging Predicts Deep Brain Stimulation Outcome in Craniocervical Dystonia
Background: Deep brain stimulation (DBS) is an established treatment for craniocervical dystonia (CCD), yet postoperative benefit varies widely and cannot be estimated before surgery. Resting‐state functional MRI (rs‐fMRI) has shown prognostic value across DBS indications. The objective of this study was to develop and externally validate preoperative rs‐fMRI models estimating DBS response in CCD. Methods: Forty‐two patients from two independent centers underwent preoperative 3 T rs‐fMRI (discovery, n = 26; validation, n = 16). Using 12 literature‐informed, symptom‐relevant regions of interest, we quantified the amplitude of low‐frequency fluctuation as a measure of intrinsic regional neural activity. We applied regularized modeling to classify super‐responders, distinguish responders from non‐responders, and estimate improvement in Burke–Fahn–Marsden Dystonia Rating Scale motor subscore. Results: When applied to the validation cohort, the imaging models achieved a three‐category classification accuracy of 75.0% (50.5%–89.8%) using a sequential two‐step procedure ( P perm = 0.002). Predicted continuous improvement was also correlated with empirical improvement ( R ext = 0.65, Q 2 = 0.34, P perm = 0.004). Within the discovery cohort, nested leave‐one‐out‐cross‐validation, in which feature selection and decision‐threshold derivation were repeated independently within each training fold, yielded areas under the curve (AUCs) of 0.73 (0.50–0.96) and 0.77 (0.51–1.00). Across models, baseline primary motor cortex activity was consistently associated with diminished postoperative benefit. Conclusions: Preoperative rs‐fMRI captures clinically relevant variation in baseline brain state in CCD, with predictive performance supported in an external validation. These findings provide preliminary support for rs‐fMRI as a potential source of information to aid patient counseling and clinical decision‐making, pending prospective validation. © 2026 International Parkinson and Movement Disorder Society.
- 12 October 2026
- Published by Wiley in Movement Disorders
Preoperative Functional Imaging Predicts Deep Brain Stimulation Outcome in Craniocervical Dystonia
Background: Deep brain stimulation (DBS) is an established treatment for craniocervical dystonia (CCD), yet postoperative benefit varies widely and cannot be estimated before surgery. Resting‐state functional MRI (rs‐fMRI) has shown prognostic value across DBS indications. The objective of this study was to develop and externally validate preoperative rs‐fMRI models estimating DBS response in CCD. Methods: Forty‐two patients from two independent centers underwent preoperative 3 T rs‐fMRI (discovery, n = 26; validation, n = 16). Using 12 literature‐informed, symptom‐relevant regions of interest, we quantified the amplitude of low‐frequency fluctuation as a measure of intrinsic regional neural activity. We applied regularized modeling to classify super‐responders, distinguish responders from non‐responders, and estimate improvement in Burke–Fahn–Marsden Dystonia Rating Scale motor subscore. Results: When applied to the validation cohort, the imaging models achieved a three‐category classification accuracy of 75.0% (50.5%–89.8%) using a sequential two‐step procedure ( P perm = 0.002). Predicted continuous improvement was also correlated with empirical improvement ( R ext = 0.65, Q 2 = 0.34, P perm = 0.004). Within the discovery cohort, nested leave‐one‐out‐cross‐validation, in which feature selection and decision‐threshold derivation were repeated independently within each training fold, yielded areas under the curve (AUCs) of 0.73 (0.50–0.96) and 0.77 (0.51–1.00). Across models, baseline primary motor cortex activity was consistently associated with diminished postoperative benefit. Conclusions: Preoperative rs‐fMRI captures clinically relevant variation in baseline brain state in CCD, with predictive performance supported in an external validation. These findings provide preliminary support for rs‐fMRI as a potential source of information to aid patient counseling and clinical decision‐making, pending prospective validation. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 15 April 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
What factors influence the length of stay and readmission after deep brain stimulation surgery? a tertiary centre study
Purpose: Deep Brain Stimulation (DBS) is a well-established treatment for refractory movement disorders. However, there are surgical risks and it often includes in-patient hospital admission. The aim is to review key factors associated with prolonged length of stay (LoS)(defined here as > 2 nights), and readmission within six months. Methods: We retrospectively reviewed medical records of patients who underwent DBS insertion between October 2016 and September 2024 in our tertiary centre. Patient and operative factors were reviewed. Results: 397 DBS procedures(388 patients) were included. Parkinson’s disease (PD) patients constitute majority(73%), followed by Essential Tremor(13%). Mean LoS were 2.39 ± 0.2 and 2.48 ± 0.5 nights, respectively. Within PD cohort, older age and use of blood thinners were associated with increased LoS. Other factors such as gender, baseline Unified Parkinson's Disease Rating Scale-3 score, symptom duration, and operating time were not statistically significant. Readmission rate was 10.3%(41/397), with majority secondary to infection(20/41) or planned readmission(13/41). Excluding planned readmissions, average LoS during readmission was 13.4 ± 0.6 nights, with majority readmitted > 30 days post-discharge (15/27). Within PD, readmission rate was 6.9%(19/276), with skull-mounted implant use identified as risk factor. Conclusions: This study identified risk factors for prolonged hospital stay after DBS surgeries, with our surgical workflow, in a publicly-funded healthcare system. We also captured factors associated with readmission within six months, which is a much longer timeframe than most studies in literature. This provides information to facilitate prehabilitation, resource allocation, and patient counselling to optimise patient outcome and reduce treatment costs. Further studies are warranted to confirm these findings, especially with different DBS techniques and workflows.
- 15 April 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
Open AccessWhat factors influence the length of stay and readmission after deep brain stimulation surgery? a tertiary centre study
Purpose: Deep Brain Stimulation (DBS) is a well-established treatment for refractory movement disorders. However, there are surgical risks and it often includes in-patient hospital admission. The aim is to review key factors associated with prolonged length of stay (LoS)(defined here as > 2 nights), and readmission within six months. Methods: We retrospectively reviewed medical records of patients who underwent DBS insertion between October 2016 and September 2024 in our tertiary centre. Patient and operative factors were reviewed. Results: 397 DBS procedures(388 patients) were included. Parkinson’s disease (PD) patients constitute majority(73%), followed by Essential Tremor(13%). Mean LoS were 2.39 ± 0.2 and 2.48 ± 0.5 nights, respectively. Within PD cohort, older age and use of blood thinners were associated with increased LoS. Other factors such as gender, baseline Unified Parkinson's Disease Rating Scale-3 score, symptom duration, and operating time were not statistically significant. Readmission rate was 10.3%(41/397), with majority secondary to infection(20/41) or planned readmission(13/41). Excluding planned readmissions, average LoS during readmission was 13.4 ± 0.6 nights, with majority readmitted > 30 days post-discharge (15/27). Within PD, readmission rate was 6.9%(19/276), with skull-mounted implant use identified as risk factor. Conclusions: This study identified risk factors for prolonged hospital stay after DBS surgeries, with our surgical workflow, in a publicly-funded healthcare system. We also captured factors associated with readmission within six months, which is a much longer timeframe than most studies in literature. This provides information to facilitate prehabilitation, resource allocation, and patient counselling to optimise patient outcome and reduce treatment costs. Further studies are warranted to confirm these findings, especially with different DBS techniques and workflows.
- Top Cited PapersOpen Access
- 17 March 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (3) , 103076
Transcranial ultrasound neuromodulation: A registry-based analysis of global clinical trials
- 17 March 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (3) , 103076
Top Cited PapersOpen AccessTranscranial ultrasound neuromodulation: A registry-based analysis of global clinical trials
- Open Access
- 6 March 2026
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 104 (5) , 360-368
Is It Safe to Have Deep Brain Stimulation after MRI-Guided Focused Ultrasound Ablation? A Report of Three Cases and Review of Literature
Introduction: MRI-guided focused ultrasound (MRgFUS) ablation has become increasingly utilised for movement disorders since its approval by the US Food and Drug Administration (FDA) in the treatment of unilateral essential tremor (ET) in 2016. While most patients achieve significant improvement in their symptoms, a proportion of ET patients experience tremor recurrence. Deep brain stimulation (DBS) is a potential rescue therapy post-MRgFUS. However, the safety profile of such scenarios is currently unknown. Case Presentations: Here, we report 3 ET patients who previously underwent MRgFUS of the ventral intermediate nucleus of the thalamus (Vim) and subsequently had DBS insertion due to tremor recurrence. Three patients (ranging from 58 to 85 years of age; one female) presented with a history of refractory ET. Patient 1 had left Vim MRgFUS and then left Vim DBS. However, the tremor control was still inadequate, and he had a further revision DBS surgery where two electrodes were inserted into left Vim. Patient 2 had two MRgFUS procedures in left Vim and then underwent left Vim DBS insertion due to hand tremor recurrence. Patient 3 had left Vim MRgFUS and then bilateral Vim DBS due to midline tremor. Patients 2 and 3 experienced substantial improvement in symptoms after DBS, but patient 1 only had minimal improvement. There were no surgical complications and no readmission within 30 days. Conclusions: This case series demonstrates that insertion of DBS electrodes in the vicinity of prior MRgFUS site can be safe. These findings have important implications for pre-operative counselling of patients with ET with high surgical risks, as well as supporting MRgFUS as a first-line therapy in selected patients. Further studies with larger population will delineate the optimal timeline where DBS may be safely performed in this population, as well as the long-term therapeutic effect of such rescue intervention.
- 6 March 2026
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 104 (5) , 360-368
Open AccessIs It Safe to Have Deep Brain Stimulation after MRI-Guided Focused Ultrasound Ablation? A Report of Three Cases and Review of Literature
Introduction: MRI-guided focused ultrasound (MRgFUS) ablation has become increasingly utilised for movement disorders since its approval by the US Food and Drug Administration (FDA) in the treatment of unilateral essential tremor (ET) in 2016. While most patients achieve significant improvement in their symptoms, a proportion of ET patients experience tremor recurrence. Deep brain stimulation (DBS) is a potential rescue therapy post-MRgFUS. However, the safety profile of such scenarios is currently unknown. Case Presentations: Here, we report 3 ET patients who previously underwent MRgFUS of the ventral intermediate nucleus of the thalamus (Vim) and subsequently had DBS insertion due to tremor recurrence. Three patients (ranging from 58 to 85 years of age; one female) presented with a history of refractory ET. Patient 1 had left Vim MRgFUS and then left Vim DBS. However, the tremor control was still inadequate, and he had a further revision DBS surgery where two electrodes were inserted into left Vim. Patient 2 had two MRgFUS procedures in left Vim and then underwent left Vim DBS insertion due to hand tremor recurrence. Patient 3 had left Vim MRgFUS and then bilateral Vim DBS due to midline tremor. Patients 2 and 3 experienced substantial improvement in symptoms after DBS, but patient 1 only had minimal improvement. There were no surgical complications and no readmission within 30 days. Conclusions: This case series demonstrates that insertion of DBS electrodes in the vicinity of prior MRgFUS site can be safe. These findings have important implications for pre-operative counselling of patients with ET with high surgical risks, as well as supporting MRgFUS as a first-line therapy in selected patients. Further studies with larger population will delineate the optimal timeline where DBS may be safely performed in this population, as well as the long-term therapeutic effect of such rescue intervention.
- Open Access
- 16 December 2025
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 40 (4) , 1-15
Cerebral blood flow and modern approaches for clinical assessment & monitoring: a view to the future
Cerebral blood flow (CBF) is under homeostatic control via cerebral autoregulation, maintaining a constant blood supply to brain parenchyma by integrating myogenic, metabolic, and neurogenic inputs across the neurovascular unit to stabilise perfusion despite physiological variations in cerebral perfusion pressure. While the mechanisms that underpin the control of CBF have been extensively investigated, this narrative review aims to holistically synthesise key findings for clinicians and researchers across healthy and diseased states. We first summarise autoregulatory inputs, cellular effectors, and typical stimuli/responses (with practical caveats including non-linearity, frequency dependence, and pressure-passivity). We then discuss monitoring approaches for assessing CBF and contrast cross-sectional techniques with portable bedside modalities, highlighting what each primarily measures (perfusion, velocity, oxygenation proxy, or flow index), their typical applications, and key constraints (radiation exposure, invasiveness, operator dependence, penetration depth, quantification). For historical context, we briefly note invasive monitors that remain selectively indispensable within multimodal neurocritical care. Looking forward, we outline emerging directions that prioritise non- and minimally-invasive solutions, including photoacoustic imaging, functional ultrasound, diffuse optical methods, speckle-based optics, and machine learning-enhanced post-processing, alongside hybrid multimodal integration. Collectively, these developments aim to improve accuracy, repeatability, and scalability of CBF monitoring and to support individualised decision-making across the clinical neurosciences.
- 16 December 2025
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 40 (4) , 1-15
Open AccessCerebral blood flow and modern approaches for clinical assessment & monitoring: a view to the future
Cerebral blood flow (CBF) is under homeostatic control via cerebral autoregulation, maintaining a constant blood supply to brain parenchyma by integrating myogenic, metabolic, and neurogenic inputs across the neurovascular unit to stabilise perfusion despite physiological variations in cerebral perfusion pressure. While the mechanisms that underpin the control of CBF have been extensively investigated, this narrative review aims to holistically synthesise key findings for clinicians and researchers across healthy and diseased states. We first summarise autoregulatory inputs, cellular effectors, and typical stimuli/responses (with practical caveats including non-linearity, frequency dependence, and pressure-passivity). We then discuss monitoring approaches for assessing CBF and contrast cross-sectional techniques with portable bedside modalities, highlighting what each primarily measures (perfusion, velocity, oxygenation proxy, or flow index), their typical applications, and key constraints (radiation exposure, invasiveness, operator dependence, penetration depth, quantification). For historical context, we briefly note invasive monitors that remain selectively indispensable within multimodal neurocritical care. Looking forward, we outline emerging directions that prioritise non- and minimally-invasive solutions, including photoacoustic imaging, functional ultrasound, diffuse optical methods, speckle-based optics, and machine learning-enhanced post-processing, alongside hybrid multimodal integration. Collectively, these developments aim to improve accuracy, repeatability, and scalability of CBF monitoring and to support individualised decision-making across the clinical neurosciences.
- 24 October 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 293, 118151
A multimodal platform for real-time neurochemical and electrophysiologic monitoring for intraoperative neurosurgical applications
- 24 October 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 293, 118151
A multimodal platform for real-time neurochemical and electrophysiologic monitoring for intraoperative neurosurgical applications
- Open Access
- 17 March 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (2) , 025058
Micromagnetic stimulation (μMS) controls dopamine release: an in vivo study using WINCS Harmoni
Research into the role of neurotransmitters in regulating normal and pathologic brain functions has made significant progress. Yet, clinical trials that aim to improve therapeutic interventions do not take advantage of the in vivo changes in the neurochemistry that occur in real time during disease progression, drug interactions or response to pharmacological, cognitive, behavioral, and neuromodulation therapies. In this work, we used the WINCS Harmoni tool to study the real time in vivo changes in dopamine release in rodent brains for the micromagnetic neuromodulation therapy. Although still in its infancy, micromagnetic stimulation (μMS) using micro-meter sized coils or microcoils (μcoils) has shown incredible promise in spatially selective, galvanic contact free and highly focal neuromodulation. These μcoils are powered by a time-varying current which generates a magnetic field. As per Faraday’s Laws of Electromagnetic Induction, this magnetic field induces an electric field in a conducting medium (here, the brain tissues). We used a solenoidal-shaped μcoil to stimulate the medial forebrain bundle (MFB) of the rodent brain in vivo. The evoked in vivo dopamine releases in the striatum were tracked in real time by carbon fiber microelectrodes (CFM) using fast scan cyclic voltammetry (FSCV). Our experiments report that μcoils can successfully activate the MFB in rodent brains, triggering dopamine release in vivo. We further show that the successful release of dopamine upon micromagnetic stimulation is dependent on the orientation of the μcoil. Furthermore, varied intensities of μMS can control the concentration of dopamine releases in the striatum. This work helps us better understand the brain and its conditions arising from a new therapeutic intervention, like μMS, at the level of neurotransmitter release. Despite its early stage, this study potentially paves the path for μMS to enter the clinical world as a precisely controlled and optimized neuromodulation therapy.
- 17 March 2025
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (2) , 025058
Open AccessMicromagnetic stimulation (μMS) controls dopamine release: an in vivo study using WINCS Harmoni
Research into the role of neurotransmitters in regulating normal and pathologic brain functions has made significant progress. Yet, clinical trials that aim to improve therapeutic interventions do not take advantage of the in vivo changes in the neurochemistry that occur in real time during disease progression, drug interactions or response to pharmacological, cognitive, behavioral, and neuromodulation therapies. In this work, we used the WINCS Harmoni tool to study the real time in vivo changes in dopamine release in rodent brains for the micromagnetic neuromodulation therapy. Although still in its infancy, micromagnetic stimulation (μMS) using micro-meter sized coils or microcoils (μcoils) has shown incredible promise in spatially selective, galvanic contact free and highly focal neuromodulation. These μcoils are powered by a time-varying current which generates a magnetic field. As per Faraday’s Laws of Electromagnetic Induction, this magnetic field induces an electric field in a conducting medium (here, the brain tissues). We used a solenoidal-shaped μcoil to stimulate the medial forebrain bundle (MFB) of the rodent brain in vivo. The evoked in vivo dopamine releases in the striatum were tracked in real time by carbon fiber microelectrodes (CFM) using fast scan cyclic voltammetry (FSCV). Our experiments report that μcoils can successfully activate the MFB in rodent brains, triggering dopamine release in vivo. We further show that the successful release of dopamine upon micromagnetic stimulation is dependent on the orientation of the μcoil. Furthermore, varied intensities of μMS can control the concentration of dopamine releases in the striatum. This work helps us better understand the brain and its conditions arising from a new therapeutic intervention, like μMS, at the level of neurotransmitter release. Despite its early stage, this study potentially paves the path for μMS to enter the clinical world as a precisely controlled and optimized neuromodulation therapy.
- Open Access
- 25 April 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (10) , 3076-3085
Resolution of tonic concentrations of highly similar neurotransmitters using voltammetry and deep learning
With advances in our understanding regarding the neurochemical underpinnings of neurological and psychiatric diseases, there is an increased demand for advanced computational methods for neurochemical analysis. Despite having a variety of techniques for measuring tonic extracellular concentrations of neurotransmitters, including voltammetry, enzyme-based sensors, amperometry, and in vivo microdialysis, there is currently no means to resolve concentrations of structurally similar neurotransmitters from mixtures in the in vivo environment with high spatiotemporal resolution and limited tissue damage. Since a variety of research and clinical investigations involve brain regions containing electrochemically similar monoamines, such as dopamine and norepinephrine, developing a model to resolve the respective contributions of these neurotransmitters is of vital importance. Here we have developed a deep learning network, DiscrimNet, a convolutional autoencoder capable of accurately predicting individual tonic concentrations of dopamine, norepinephrine, and serotonin from both in vitro mixtures and the in vivo environment in anesthetized rats, measured using voltammetry. The architecture of DiscrimNet is described, and its ability to accurately predict in vitro and unseen in vivo concentrations is shown to vastly outperform a variety of shallow learning algorithms previously used for neurotransmitter discrimination. DiscrimNet is shown to generalize well to data captured from electrodes unseen during model training, eliminating the need to retrain the model for each new electrode. DiscrimNet is also shown to accurately predict the expected changes in dopamine and serotonin after cocaine and oxycodone administration in anesthetized rats in vivo. DiscrimNet therefore offers an exciting new method for real-time resolution of in vivo voltammetric signals into component neurotransmitters.
- 25 April 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (10) , 3076-3085
Open AccessResolution of tonic concentrations of highly similar neurotransmitters using voltammetry and deep learning
With advances in our understanding regarding the neurochemical underpinnings of neurological and psychiatric diseases, there is an increased demand for advanced computational methods for neurochemical analysis. Despite having a variety of techniques for measuring tonic extracellular concentrations of neurotransmitters, including voltammetry, enzyme-based sensors, amperometry, and in vivo microdialysis, there is currently no means to resolve concentrations of structurally similar neurotransmitters from mixtures in the in vivo environment with high spatiotemporal resolution and limited tissue damage. Since a variety of research and clinical investigations involve brain regions containing electrochemically similar monoamines, such as dopamine and norepinephrine, developing a model to resolve the respective contributions of these neurotransmitters is of vital importance. Here we have developed a deep learning network, DiscrimNet, a convolutional autoencoder capable of accurately predicting individual tonic concentrations of dopamine, norepinephrine, and serotonin from both in vitro mixtures and the in vivo environment in anesthetized rats, measured using voltammetry. The architecture of DiscrimNet is described, and its ability to accurately predict in vitro and unseen in vivo concentrations is shown to vastly outperform a variety of shallow learning algorithms previously used for neurotransmitter discrimination. DiscrimNet is shown to generalize well to data captured from electrodes unseen during model training, eliminating the need to retrain the model for each new electrode. DiscrimNet is also shown to accurately predict the expected changes in dopamine and serotonin after cocaine and oxycodone administration in anesthetized rats in vivo. DiscrimNet therefore offers an exciting new method for real-time resolution of in vivo voltammetric signals into component neurotransmitters.
- Open Access
Micromagnetic Stimulation (μMS) Controls Dopamine Release: An in vivo Study Using WINCS Harmoni
Objective: Research into the role of neurotransmitters in regulating normal and pathologic brain functions has made significant progress. Yet, clinical trials that aim to improve therapeutic interventions do not take advantage of the in vivo changes in the neurochemistry that occur in real time during disease progression, drug interactions or response to pharmacological, cognitive, behavioral, and neuromodulation therapies. In this work, we used the WINCS Harmoni tool to study the real time in vivo changes in dopamine release in rodent brains for the micromagnetic neuromodulation therapy. Approach: Although still in its infancy, micromagnetic stimulation (μMS) using micro-meter sized coils or microcoils (μcoils) has shown incredible promise in spatially selective, galvanic contact free and highly focal neuromodulation. These μcoils are powered by a time-varying current which generates a magnetic field. As per Faraday’s Laws of Electromagnetic Induction, this magnetic field induces an electric field in a conducting medium (here, the brain tissues). We used a solenoidal-shaped μcoil to stimulate the medial forebrain bundle (MFB) of the rodent brain in vivo . The evoked in vivo dopamine releases in the striatum were tracked in real time by carbon fiber microelectrodes (CFM) using fast scan cyclic voltammetry (FSCV). Results: Our experiments report that μcoils can successfully activate the MFB in rodent brains, triggering dopamine release in vivo . We further show that the successful release of dopamine upon micromagnetic stimulation is dependent on the orientation of the μcoil. Furthermore, varied intensities of μMS can control the concentration of dopamine releases in the striatum. Significance: This work helps us better understand the brain and its conditions arising from a new therapeutic intervention, like μMS, at the level of neurotransmitter release. Despite its early stage, this study potentially paves the path for μMS to enter the clinical world as a precisely controlled and optimized neuromodulation therapy.
Open AccessMicromagnetic Stimulation (μMS) Controls Dopamine Release: An in vivo Study Using WINCS Harmoni
Objective: Research into the role of neurotransmitters in regulating normal and pathologic brain functions has made significant progress. Yet, clinical trials that aim to improve therapeutic interventions do not take advantage of the in vivo changes in the neurochemistry that occur in real time during disease progression, drug interactions or response to pharmacological, cognitive, behavioral, and neuromodulation therapies. In this work, we used the WINCS Harmoni tool to study the real time in vivo changes in dopamine release in rodent brains for the micromagnetic neuromodulation therapy. Approach: Although still in its infancy, micromagnetic stimulation (μMS) using micro-meter sized coils or microcoils (μcoils) has shown incredible promise in spatially selective, galvanic contact free and highly focal neuromodulation. These μcoils are powered by a time-varying current which generates a magnetic field. As per Faraday’s Laws of Electromagnetic Induction, this magnetic field induces an electric field in a conducting medium (here, the brain tissues). We used a solenoidal-shaped μcoil to stimulate the medial forebrain bundle (MFB) of the rodent brain in vivo . The evoked in vivo dopamine releases in the striatum were tracked in real time by carbon fiber microelectrodes (CFM) using fast scan cyclic voltammetry (FSCV). Results: Our experiments report that μcoils can successfully activate the MFB in rodent brains, triggering dopamine release in vivo . We further show that the successful release of dopamine upon micromagnetic stimulation is dependent on the orientation of the μcoil. Furthermore, varied intensities of μMS can control the concentration of dopamine releases in the striatum. Significance: This work helps us better understand the brain and its conditions arising from a new therapeutic intervention, like μMS, at the level of neurotransmitter release. Despite its early stage, this study potentially paves the path for μMS to enter the clinical world as a precisely controlled and optimized neuromodulation therapy.
- 19 February 2023
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27 (1) , 200-208
Implantable Subdural Cortical Stimulation for Chronic Intractable Pain Treatment—The Mayo Experience and Review of Literature
- 19 February 2023
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27 (1) , 200-208
Implantable Subdural Cortical Stimulation for Chronic Intractable Pain Treatment—The Mayo Experience and Review of Literature